Gilead Sciences, Inc (GIS) – tečaj delnic in novice

Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy. In 1987, Michael L. Riordan founded the company under the name Oligogen. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs including Tamiflu and Vistide that decade. In the 2000s, Gilead began evolving from a biotechnology company into a large pharmaceutical company, through acquisitions and investments, acquiring several subsidiaries. Gilead is a member of the Nasdaq-100 and the S&P 100. The company has faced criticism over its business practices, including extremely high pricing of drugs such as Sovaldi and Truvada in the United States relative to production cost and cost in the developing world. Wikipedia

Vizitka: Gilead Sciences, Inc

Generalni direktorDaniel O'Day

Št. zaposlenih17 tis.

Ustanovljeno22. jun. 1987

SedežFoster City, Kalifornija, Združene države Amerike

Sektor-

Spletno mestogilead.com

Vse vrednosti v valuti USD	sep. 2025	dec. 2025	mar. 2026	jun. 2026
Prihodek	7,77 mrd.	7,92 mrd.	6,96 mrd.	7,80 mrd.
Strošek prodanega blaga	1,57 mrd.	1,62 mrd.	1,44 mrd.	1,58 mrd.
Stroški materiala in storitev	1,57 mrd.	1,62 mrd.	1,44 mrd.	1,58 mrd.
Stroški raziskav in razvoja	1,33 mrd.	1,57 mrd.	1,36 mrd.	1,69 mrd.
Skupni stroški raziskav in razvoja	-	-	-	-
Stroški prodaje, splošni in administrativni stroški	1,35 mrd.	1,78 mrd.	1,43 mrd.	1,91 mrd.
Operativni strošek	2,69 mrd.	3,34 mrd.	2,78 mrd.	3,60 mrd.
Skupni operativni stroški	4,26 mrd.	4,96 mrd.	4,23 mrd.	5,18 mrd.
Prihodek iz poslovanja	3,51 mrd.	2,96 mrd.	2,73 mrd.	2,63 mrd.
Drug prihodek, ki ne izhaja iz poslovanja	−23,00 mio.	51,00 mio.	−8,00 mio.	-
Zaslužek pred obdavčitvijo z vključenimi izrednimi postavkami	3,64 mrd.	2,08 mrd.	2,58 mrd.	−10,25 mrd.
Zaslužek pred obdavčitvijo brez izrednih postavk	3,34 mrd.	2,80 mrd.	2,59 mrd.	2,42 mrd.
Odhodek iz obdavčitve dobička	589,00 mio.	−105,00 mio.	559,00 mio.	242,00 mio.
Dejanska davčna stopnja	16,18 %	−5,05 %	21,67 %	−2,36 %
Drugi operativni stroški	-	-	-	-
Čisti prihodek	3,05 mrd.	2,18 mrd.	2,02 mrd.	−10,50 mrd.
Neto stopnja dobička	39,28 %	27,55 %	29,04 %	−134,51 %
Čisti dobiček na delnico	2,47	1,86	2,03	−6,75
Prihodki iz obresti in naložb	88,00 mio.	95,00 mio.	95,00 mio.	45,00 mio.
Obrestni odhodki	−256,00 mio.	−255,00 mio.	−240,00 mio.	−247,00 mio.
Neto obrestni odhodki	−168,00 mio.	−160,00 mio.	−145,00 mio.	−202,00 mio.
Stroški amortizacije	-	-	-	-
EBITDA	4,20 mrd.	3,65 mrd.	3,42 mrd.	3,33 mrd.
Dobiček ali izguba pri prodaji sredstev	-	-	-	-

Vprašajte kar koli